ClinicalTrials.gg
RecruitingNCT04910464Updated Aug 5, 2025

Early Tranexamic Acid and Modulating the Inflammatory Response in Sepsis

A Phase 3 interventional study of Tranexamic acid and 0.9% saline in Sepsis, sponsored by Assiut University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-08-05.

Sponsored by Assiut University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2021; still recruiting 5 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Sepsis by Assiut University — 23 open to participants now, 23 under way, 1 of them phase 3. Sepsis · Assiut University.

Started
2021
with 2 others
Phase 3
Only one
of the 33
Primary completion
2027-01
later than 8 of 22 live
Registered
6th of 33
by date

Among the 33 studies in Sepsis by Assiut University, this one is one of 3 that started in 2021, is the only one in phase 3, reaches primary completion later than 8 of the 22 other live ones, and was the 6th registered.

Sepsis

2,422 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

23 of the 33 studies in Sepsis by Assiut University are open now, in 1 country. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 23 open studies →

Where they have run

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Sepsis by Assiut University, or all of them as a file.
02

Study summary

In this study, our aim is to investigate the role tranexamic acid in modulating inflammation in patients with sepsis.

Read the detailed description

A written informed consent will be taken from the patients or their relatives.Patients will be assigned randomly to two groups (40 subjects each) with qSOFA ≥2.

In (Group T) administer 1 gram of tranexamic acid (TXA) in 100 ml of 0.9% normal saline, intravenous over 10 minutes as soon as possible but no later than three hours after diagnosis, infuse a second gram of tranexamic acid (TXA) IV over 8 hours in 0.9% normal saline for the first 3 days. In (Group C) administer the same volume (100 ml normal saline)and same duration (first three days)for controlled patients.

03

Conditions studied

  • Sepsis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (age 18-65 years) of (ASA) I-II who will be diagnosed with sepsis by qSOFA ≥2
  • \& needed ICU admission.

Exclusion criteria

Exclusion Criteria:

  • Chronic renal failure
  • Liver cirrhosis
  • Bleeding disorders or current anticoagulant therapy
  • Pregnancy or breastfeeding
  • Impaired color vision
  • Severe vascular ischemia, history of venous thrombosis \& pulmonary embolism
  • Long term treatment with acetylsalicylic acid or non-steroidal anti-inflammatory drugs not discontinued before ICU admission
  • Allergy to tranexamic acid (TXA)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Tranexamic acid

    Give 1 gram of TXA in 100 ml of 0.9% normal saline, intravenous over 10 minutes as soon as possible but no later than three hours after diagnosis, infuse a second gram of TXA IV over 8 hours in 0.9% normal saline for the first 3 days.

    Drug: Tranexamic acid

  • Placebo comparator
    Saline placebo

    Give the same volume (100 ml normal saline) and same duration (first three days).

    Other: 0.9% saline

Interventions

  • administer 1 gram of TXA in 100 ml of 0.9% normal saline, intravenous over 10 minutes as soon as possible but no later than three hours after diagnosis, infuse a second gram of TXA IV over 8 hours in 0.9% normal saline for first 3 days.

    Also known as: Cyclokapron

  • Other0.9% saline

    administer the same volume (100ml normal saline) and same duration (first three days).

    Also known as: Normal saline

06

What researchers measure

Primary outcomes

  1. ICU mortality

    Short-term ICU mortality within 7days of admission and intervention

    Time frame: 7days

Secondary outcomes

  1. Neutrophil/lymphocyte ratio (NLR)

    From complete blood count, divide absolute number of neutrophils on lymphocyte to assess and follow up the inflammatory response in sepsis

    Time frame: 4 days

  2. Interleukin-6 (IL-6) serum level

    Measurement of interleukin-6 (IL-6) serum level to assess and follow up the inflammatory response in sepsis

    Time frame: 4 days

  3. Glasgow coma scale (GCS)

    Assessing the conscious level of patients by Glasgow Coma Scale (3\_15)after ICU admission and intervention start give an idea on brain dysfunction in sepsis where high scores are associated with low mortality and low scores are associated with high mortality

    Time frame: 5 days

  4. ICU stay

    Days of patients admission in ICU

    Time frame: 7 days

  5. Length of hospitalization

    Days of patients admission in hospital

    Time frame: 7 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2021 (actual). Primary completion is estimated for Jan 2027, 67 months after the start.

Of 58 non-industry phase 3 interventional studies under Sepsis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 63. This study's planned 67 months is above that.

Counting every sponsor, half of 66 studies reached it within 39 months; a quarter within 24 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2021
First posted
Jun 2, 2021
StartActual
Jun 5, 2021
Primary completionEst.
Jan 10, 2027
CompletionEst.
Jan 30, 2027
Last update
Aug 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04910464
Lead sponsor
Assiut University
Responsible party
Omar Makram Soliman (Lecturer of anesthesia and ICU, Assiut University) — Principal investigator
First posted
Jun 2, 2021
Start date
Jun 5, 2021
Primary completion
Jan 10, 2027 (estimated)
Completion
Jan 30, 2027 (estimated)
Last update
Aug 5, 2025

Study contacts

Omar Soliman
Contact
omarmakram347@yahoo.com
01101266040
Omar Soliman, MD
principal investigator · Omar makram

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tranexamic Acid

Start the discussion